We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alterity Therapeutics Ltd (PK) | USOTC:PRNAF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00292 | 0.0023 | 0.0038 | 0.00 | 16:50:55 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2023
Alterity Therapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
99.1 | Results of Annual General Meeting |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Alterity Therapeutics Limited | ||
By: | /s/ Geoffrey P. Kempler | |
Geoffrey P. Kempler | ||
Chairman |
Date: November 29, 2023
2
Exhibit 99.1
Results of Annual General Meeting
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 29 November 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) advises that all resolutions considered at the Annual General Meeting held today were carried by poll.
In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution are attached.
Phillip Hains
Company Secretary
Alterity Therapeutics Limited
ACN 080 699 065
Level 3, 62 Lygon Street Carlton Victoria 3053 Australia
www.alteritytherapeutics.com
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
Resolution details |
Instructions given
to validly appointed proxies |
Number of votes cast
on the poll |
Resolution | ||||||
Resolution |
Resolution |
For | Against |
Proxy’s |
Abstain | For | Against | Abstain* |
Carried / |
1 Non-binding resolution to adopt Remuneration Report | Ordinary |
80,616,129 76.83% |
21,954,866 20.92% |
2,360,040 2.25% |
14,602,600 |
89,426,169 80.29% |
21,954,866 19.71% |
14,602,600 | Carried |
2 Re-Election of Director Mr. Peter Marks | Ordinary |
106,311,290 85.25% |
16,351,485 13.11% |
2,043,660 1.64% |
12,043,800 |
118,077,176 87.84% |
16,351,485 12.16% |
12,043,800 | Carried |
3 Re-Election of Director Mr. Lawrence Gozlan | Ordinary |
106,475,730 85.62% |
15,842,045 12.74% |
2,043,660 1.64% |
12,022,800 |
118,241,616 88.18% |
15,842,045 11.82% |
12,022,800 | Carried |
4 Ratification of prior issue of shares (Placement March 2023) | Ordinary |
115,193,651 85.81% |
17,027,399 12.68% |
2,033,660 1.51% |
3,043,925 |
126,949,537 88.17% |
17,027,399 11.83% |
3,043,925 | Carried |
5 Approval of 10% Placement Facility | Special |
111,296,889 83.43% |
19,861,399 14.89% |
2,243,660 1.68% |
3,896,687 |
123,262,775 86.12% |
19,861,399 13.88% |
3,896,687 | Carried |
* | Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. |
1/1
1 Year Alterity Therapeutics (PK) Chart |
1 Month Alterity Therapeutics (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions